Arcadia Biosciences, Inc. Total Assets

• Arcadia Biosciences, Inc. showed a decrease of -51.6% in Total Assets from 2024 to 2025.
• This data is from Arcadia Biosciences, Inc.'s annual report (Form 10-K), filed with the SEC on March 26, 2026.
• XBRL data for this metric is available from 2014 to 2025 (12 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
• Quarterly values from 10-Q filings: Q1 2015: $19.42 million | Q2 2015: $84.99 million | Q3 2015: $79.97 million | Q1 2016: $70.11 million | Q2 2016: $65.71 million | Q3 2016: $61.59 million | Q1 2017: $52.65 million | Q2 2017: $48.43 million | Q3 2017: $18.98 million | Q1 2018: $22.60 million | Q2 2018: $31.13 million | Q3 2018: $27.22 million | Q1 2019: $21.95 million | Q2 2019: $25.35 million | Q3 2019: $37.30 million | Q1 2020: $32.25 million | Q2 2020: $37.78 million | Q3 2020: $33.88 million | Q1 2021: $70.80 million | Q2 2021: $70.80 million | Q3 2021: $59.23 million | Q1 2022: $38.80 million | Q2 2022: $35.01 million | Q3 2022: $34.47 million | Q1 2023: $30.41 million | Q2 2023: $26.80 million | Q3 2023: $23.47 million | Q1 2024: $16.05 million | Q2 2024: $17.37 million | Q3 2024: $15.24 million | Q1 2025: $12.99 million | Q2 2025: $7.79 million | Q3 2025: $8.58 million.
• Over the full 12 years of available data (2014 to 2025), Arcadia Biosciences, Inc.'s Total Assets has declined by 73.7%.
• Historical annual values: Fiscal year 2025: $6.55 million | Fiscal year 2024: $13.52 million | Fiscal year 2023: $19.71 million | Fiscal year 2022: $28.92 million | Fiscal year 2021: $43.92 million | Fiscal year 2020: $47.35 million | Fiscal year 2019: $32.57 million | Fiscal year 2018: $24.02 million | Fiscal year 2017: $16.57 million | Fiscal year 2016: $56.57 million | Fiscal year 2015: $74.24 million | Fiscal year 2014: $24.89 million.
• Data sourced from SEC EDGAR public filings as of August 5, 2026.

Last verified: August 5, 2026